Contact : +1 (888) 308-1808

/

Entrada Therapeutics gets ok to start Exon 44 skipping trial in UK

As an early funder of Entrada, CureDuchenne is pleased to share that Entrada received authorization in the United Kingdom (UK) to start a Phase 1/2 trial for individuals with Duchenne amenable to exon 44 skipping. 

Part A, which is planned to start in Q2 2025, will be a multiple-ascending dose study in 24 individuals with Duchenne, with doses administered every 6 weeks.  Part B will further evaluate the optimal dose established. 

Entrada has also submitted regulatory filings to initiate trials in the US and In Europe, and those regulatory discussions are ongoing.

Press release: https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-receives-authorization-united-kingdom-0

The post Entrada Therapeutics gets ok to start Exon 44 skipping trial in UK appeared first on CureDuchenne.

Leave a Reply

Your email address will not be published. Required fields are marked *